Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer

被引:9
作者
Bellmunt, Joaquim [1 ]
Calvo, Emiliano [2 ]
Castellano, Daniel [3 ]
Angel Climent, Miguel [4 ]
Esteban, Emilio [5 ]
Garcia del Muro, Xavier [6 ]
Luis Gonzalez-Larriba, Jose [7 ]
Maroto, Pablo [8 ]
Manuel Trigo, Jose [9 ]
机构
[1] Hosp Mar, Med Oncol Serv, Barcelona 08003, Spain
[2] Hosp Valle De Hebron, Med Oncol Serv, Barcelona, Spain
[3] Hosp 12 Octubre, E-28041 Madrid, Spain
[4] Inst Valenciano Oncol, Med Oncol Serv, Valencia, Spain
[5] Hosp Univ Cent Asturias, Med Oncol Serv, Oviedo, Spain
[6] Inst Catala Oncol, Med Oncol Serv, Barcelona, Spain
[7] Hosp Clin San Carlos, Med Oncol Serv, Madrid, Spain
[8] Hosp Santa Creu & Sant Pau, Med Oncol Serv, Barcelona, Spain
[9] Hosp Virgen Victoria, Med Oncol Serv, Malaga, Spain
关键词
ENDOTHELIAL GROWTH-FACTOR; EXTRACRANIAL STEREOTACTIC RADIOTHERAPY; RANDOMIZED PHASE-II; CELL CARCINOMA; INTERFERON-ALPHA; RADICAL NEPHRECTOMY; MAMMALIAN TARGET; POSTOPERATIVE RADIOTHERAPY; DOSE INTERLEUKIN-2; PROGNOSTIC-FACTORS;
D O I
10.1007/s00280-009-0955-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For almost the last two decades, interleukin-2 and interferon-alpha have been the only systemic treatment options available for metastatic renal cell carcinoma. However, in recent years, five new targeted therapies namely sunitinib, sorafenib, temsirolimus, everolimus and bevacizumab have demonstrated clinical activity in these patients. With the availability of new targeted agents that are active in this disease, there is a need to continuously update the treatment algorithm of the disease. Due to the important advances obtained, the Spanish Oncology Genitourinary Group (SOGUG) has considered it would be useful to review the current status of the disease, including the genetic and molecular biology factors involved, the current predicting models for development of metastases as well as the role of surgery, radiotherapy and systemic therapies in the early- or late management of the disease. Based on this previous work, a treatment algorithm was developed.
引用
收藏
页码:S1 / S13
页数:13
相关论文
共 81 条
[1]   Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma [J].
Akaza, Hideyuki ;
Tsukamoto, Taiji ;
Murai, Masaru ;
Nakajima, Keiko ;
Naito, Seiji .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (10) :755-762
[2]  
Amato RJ, 2000, SEMIN ONCOL, V27, P177
[3]  
[Anonymous], J CLIN ONCOL S
[4]  
[Anonymous], J CLIN ONCOL S
[5]  
[Anonymous], 2002, AJCC CANC STAGING HD
[6]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[7]   Innovations and challenges in renal cell carcinoma: Summary statement from the second Cambridge conference [J].
Atkins, Michael B. ;
Ernstoff, Marc S. ;
Figlin, Robert A. ;
T Flaherty, Keith ;
George, Daniel J. ;
Kaelin, William G., Jr. ;
Kwon, Eugene D. ;
Libermann, Towia A. ;
Linehan, W. Marston ;
McDermott, David F. ;
Ochoa, Augusto C. ;
Pantuck, Allan J. ;
Rini, Brian I. ;
Rosen, Mark A. ;
Sosman, Jeffrey A. ;
Sukhatme, Vikas P. ;
Vieweg, Johannes W. ;
Wood, Christopher G. ;
King, Laura .
CLINICAL CANCER RESEARCH, 2007, 13 (02) :667S-670S
[8]   Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer [J].
Banks, RE ;
Tirukonda, P ;
Taylor, C ;
Hornigold, N ;
Astuti, D ;
Cohen, D ;
Maher, ER ;
Stanley, AJ ;
Harnden, P ;
Joyce, A ;
Knowles, M ;
Selby, PJ .
CANCER RESEARCH, 2006, 66 (04) :2000-2011
[9]   Prognostic factors in patients with advanced renal cell carcinoma: Development of an international kidney cancer working group [J].
Bukowski, RM ;
Negrier, S ;
Elson, P .
CLINICAL CANCER RESEARCH, 2004, 10 (18) :6310S-6314S
[10]  
Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154